WO2015028441A1 - Housing and cap for an injection device made of an outer metal part and an inner plastic part - Google Patents
Housing and cap for an injection device made of an outer metal part and an inner plastic part Download PDFInfo
- Publication number
- WO2015028441A1 WO2015028441A1 PCT/EP2014/068023 EP2014068023W WO2015028441A1 WO 2015028441 A1 WO2015028441 A1 WO 2015028441A1 EP 2014068023 W EP2014068023 W EP 2014068023W WO 2015028441 A1 WO2015028441 A1 WO 2015028441A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metal element
- plastic element
- plastic
- drug delivery
- assembly according
- Prior art date
Links
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 154
- 239000002184 metal Substances 0.000 title claims abstract description 154
- 239000004033 plastic Substances 0.000 title claims abstract description 135
- 238000002347 injection Methods 0.000 title description 5
- 239000007924 injection Substances 0.000 title description 5
- 238000012377 drug delivery Methods 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000004411 aluminium Substances 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 239000012780 transparent material Substances 0.000 claims description 2
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 54
- 108010011459 Exenatide Proteins 0.000 description 50
- 229960001519 exenatide Drugs 0.000 description 50
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 22
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 22
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000000994 depressogenic effect Effects 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000013011 mating Effects 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229920006324 polyoxymethylene Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- -1 Polyoxymethylen Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007769 metal material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000007743 anodising Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 108010015174 exendin 3 Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- XVVOERDUTLJJHN-IAEQDCLQSA-N lixisenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 XVVOERDUTLJJHN-IAEQDCLQSA-N 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004532 somatropin Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 241001223854 teleost fish Species 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31536—Blocking means to immobilize a selected dose, e.g. to administer equal doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
- A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2403—Ampoule inserted into the ampoule holder
- A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2488—Ampoule holder connected to rest of syringe via rotation, e.g. threads or bayonet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3103—Leak prevention means for distal end of syringes, i.e. syringe end for mounting a needle
- A61M2005/3104—Caps for syringes without needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31536—Blocking means to immobilize a selected dose, e.g. to administer equal doses
- A61M2005/3154—Blocking means to immobilize a selected dose, e.g. to administer equal doses limiting maximum permissible dose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
- A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
Definitions
- the present disclosure relates to an assembly for a drug delivery device. Furthermore, the present disclosure relates to a drug delivery device comprising the assembly and to a method of producing the assembly.
- Drug delivery devices in particular pen-type drug delivery devices, have application where regular injection by persons without formal medical training occurs. This may be increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease. In practice, such a drug delivery device allows a user to dispense a number of user variable doses or fixed doses of a medicament.
- An assembly for a drug delivery device comprising a metal element and a plastic element which together form a functional unit.
- the metal element provides an outer surface of the assembly.
- the outer surface is configured to be handled by a user, in particular a user of the drug delivery device.
- the outer surface may provide a supporting surface for a hand of a user during a use of the drug delivery device.
- the metal element and the plastic element are fixedly coupled to each other.
- the metal component and the plastic component are rotationally and axially fixed with respect to each other.
- a metal component forms an outer surface
- a metal surface has pleasant haptical properties to a user.
- a metal surface may feel smooth and cool.
- a metal surface may look more precious than a plastic surface.
- the assembly may have less weight than an assembly which is completely produced of metal.
- the material costs are kept low without losing functional properties.
- the plastic element may improve the stability of the metal element. Due to the plastic element, the metal element may withstand forces acting on the metal element during an assembly of the drug delivery device.
- the metal element may be dimensionally stable. Additionally, the plastic element may be moulded with features that attach to other existing inner plastic components. Furthermore, the plastic element and/or the metal element may comprise other features, such as one or more stop features, for example an '80Units stop' feature, that is/are configured or required to prevent the user from setting a dose greater than a pre-determined maximum dose.
- a stop feature may be configured so as to provide a defined rotational and/or axial stop for a dialing member of a drug delivery device, such as a dial sleeve or whatsoever. In this way, e.g.
- an axial travel of such a dialing member which corresponds to a dialed dose of a medicament can be delimited such that dose dialing can be restricted to a predetermined maximum dose.
- a stop feature on the dial sleeve may be engaged with said stop feature of the metal element or the plastic element of the assembly, thereby determining a maximum set dose.
- the assembly may form an outer housing part or a cap for a drug delivery device.
- both a housing part and a cap for a drug delivery device may be formed by a respective assembly.
- the assembly may be a part for a drug delivery device which is often touched by a user.
- the plastic element is a housing part
- the plastic element may be attached to an inner housing body.
- the inner housing body may comprise retention features that may engage with the plastic element.
- a functional unit may be an assembly which once assembled acts as one part.
- the metal element and the plastic element may be permanently or releasably coupled.
- the length of the metal element and the plastic element may be essentially equal.
- the length of the plastic element may be less than the length of the metal element.
- the length of the plastic element may be between one fourth and one half of the length of the metal element. Thereby, the plastic element may be easier and cheaper to produce.
- the metal element may comprise aluminium or another metal material.
- An outer surface of the metal element may be anodised.
- the anodising provides a high quality and hard wearing exterior surface to the metal element. Furthermore, it enables it to be given a variety of metallic colours.
- the metal element may be galvanised. Alternatively, the metal element may be surface treated by brushing.
- the metal element may be varnished with a clear coating material.
- the metal element may essentially comprise the shape of a sleeve.
- a wall thickness of the metal element may be between 0.3 mm and 0.6 mm.
- the wall thickness of the metal element may be 0.4 mm.
- the metal element may comprise a sufficient stability while having a low weight.
- the metal element may be manufactured by deep drawing.
- the metal element may comprise an end face which is inclined with respect to a longitudinal axis of the metal element.
- the end face may be inclined about 60° to 80° with respect to the longitudinal axis of the metal element.
- the plastic element may comprise Polyoxymethylen or another plastic material.
- the plastic element may be produced by mold flowing.
- the shape of the plastic element and the metal element may be adapted to each other.
- an outer surface of the plastic element may be adapted to an inner surface of the metal element in a large part. This means that only a small part of the outer surface of the plastic element, for example a part which is necessary to align the plastic element and the metal element with respect to each other, is not in contact with an inner surface of the metal element.
- the metal element comprises one or more radial lugs. The metal element and the plastic element may be held together by the radial lug of the metal extending towards the plastic element. In particular, the radial lug may engage the plastic element. Thereby, an axial and rotational position of the metal element and the plastic element with respect to each other may be maintained.
- the metal element may be connected to the plastic element by means of the radial lug.
- the lug features are preferably formed by punching.
- the metal element and the plastic element may be connected by reshaping the metal element.
- the metal element comprises one or more additional lug features, which are configured to serve as a stop feature, for example as an '80Units stop' feature, instead of the plastic element.
- the additional lug features may be folded into the metal element.
- the additional lug features do not contact the plastic element.
- the assembly comprises an aperture.
- the metal element and the plastic element may each comprise an aperture which are aligned with each other.
- the aperture in the metal element may be cut out by blanking.
- the aperture in the plastic element may be provided during the moulding process.
- the radial lug of the metal element may be located at the aperture. In order to secure the metal element and the plastic element with respect to each other, the radial lug is folded into the aperture.
- the aperture may be provided for receiving a further component.
- the aperture may be configured to receive a clip element.
- the aperture may receive a window component. In the window component, an amount of a set dose may be indicated to a user.
- the metal element and the plastic element may be secured with respect to each other by the further component being received in the aperture.
- the further component may stick through the aperture of the metal element. Thereby, the metal element and the plastic element may be held in a fixed position.
- the further component may be clipped in the plastic element.
- the metal element may comprise an aperture.
- the plastic element may be made from a transparent material.
- the window component may be comprised by the plastic element. In particular, no further window component is necessary.
- the plastic element may comprise a protrusion.
- the protrusion may be located at an axial end of the plastic element.
- the protrusion may extend in a radial outward direction.
- the metal element may extend over the plastic element until it abuts the protrusion.
- an axial position of the metal element with respect to the plastic element may be defined.
- the protrusion of the plastic element may comprise a nose which extends in a longitudinal direction. The nose may be configured to engage with a corresponding recess of the metal element. Thereby, a rotational position of the metal element with respect to the plastic element may be defined.
- a drug delivery device may comprise an assembly as described above.
- the drug delivery device may comprise further elements, such as a drive assembly, a cartridge holder and a cartridge.
- the drug delivery device may have a weight of less than 30 g.
- the drug delivery device may have a weight of less than 30 g containing a cartridge which is full with a medicament.
- the drug delivery device may have a weight of less than 30 g containing an empty cartridge. This may be achieved by the combination of a metal element and a plastic element in one functional unit.
- a drug delivery device having a weight of less than 30 g has the advantage that it is easy to handle by a user.
- the drug delivery device may be an injection device.
- the drug delivery device may be a pen-type device.
- the drug delivery device may be a fixed dose device such that the amount of medication which is delivered during one dispense operation is
- the drug delivery device may be a variable dose device such that the amount of medication which is delivered during one dispense operation may be adjusted by a user.
- the drug delivery device may be configured for multiple dose applications.
- the medication may be delivered to a user by means of a needle.
- the device may be delivered to a user in a fully assembled condition ready for use.
- the drug delivery device may be a reusable device.
- the drug delivery device may be a disposable device.
- the term "disposable" means that the drug delivery device cannot be reused after an available amount of medication has been delivered from the drug delivery device.
- the drug delivery device may be configured to deliver a liquid
- the medication may be, for example, insulin.
- a method of producing an assembly for a drug delivery device comprises the providing of a metal element and a plastic element.
- the metal element and the plastic element may have the shape of a sleeve.
- the metal element is slid over the plastic element.
- the metal element is slid over the plastic element in a longitudinal direction.
- dication preferably means a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an
- oligonucleotide or a mixture of the above-mentioned pharmaceutically active compound, wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever,
- diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever,
- ACS acute coronary syndrome
- angina myocardial infarction
- cancer macular degeneration
- inflammation hay fever
- the pharmaceutically active compound comprises at least one peptide for the treatment and/or prophylaxis of diabetes mellitus or
- the pharmaceutically active compound comprises at least one human insulin or a human insulin analogue or derivative, glucagon-like peptide (GLP-1 ) or an analogue or derivative thereof, or exendin-3 or exendin-4 or an analogue or derivative of exendin-3 or exendin-4.
- GLP-1 glucagon-like peptide
- Insulin analogues are for example Gly(A21 ), Arg(B31 ), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin;
- Des(B28-B30) human insulin Des(B27) human insulin and Des(B30) human insulin.
- Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N- palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl- LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N- palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; ⁇ 29- ⁇ -( ⁇ - carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( -carboxy
- Exendin-4 for example means Exendin-4(1 -39), a peptide of the sequence H-His-Gly- Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe- lle-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
- Exendin-4 derivatives are for example selected from the following list of compounds:
- H-(Lys)6-des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Asn-(Glu)5 des Pro36, Pro37, Pro38 [Met(O)14, Asp28] Exendin-4(1 -39)-(Lys)6-NH2, H-Lys6-des Pro36 [Met(O)14, Trp(O2)25, Asp28] Exendin-4(1 -39)-Lys6-NH2,
- Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008,
- Gonadotropine Follitropin, Lutropin, Choriongonadotropin
- Somatropine Somatropin
- Desmopressin Terlipressin
- Gonadorelin Triptorelin
- Leuprorelin Buserelin
- Nafarelin Goserelin.
- a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned
- Antibodies are globular plasma proteins (-150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
- the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
- Ig immunoglobulin
- the Ig monomer is a "Y"-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-1 10 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two ⁇ sheets create a "sandwich" shape, held together by interactions between conserved cysteines and other charged amino acids.
- Ig heavy chain There are five types of mammalian Ig heavy chain denoted by ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ .
- the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
- Distinct heavy chains differ in size and composition; a and ⁇ contain approximately 450 amino acids and ⁇ approximately 500 amino acids, while ⁇ and ⁇ have approximately 550 amino acids.
- Each heavy chain has two regions, the constant region (C H ) and the variable region (V H ).
- the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
- Heavy chains ⁇ , a and ⁇ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains ⁇ and ⁇ have a constant region composed of four immunoglobulin domains.
- variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
- the variable region of each heavy chain is approximately 1 10 amino acids long and is composed of a single Ig domain.
- immunoglobulin light chain denoted by ⁇ and ⁇ .
- a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
- CL constant domain
- VL variable domain
- the approximate length of a light chain is 21 1 to 217 amino acids.
- Each antibody contains two light chains that are always identical; only one type of light chain, K or ⁇ , is present per antibody in mammals.
- variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
- VL variable light
- VH variable heavy chain
- CDRs Complementarity Determining Regions
- an "antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
- Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab).
- the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
- F(ab')2 is divalent for antigen binding.
- the disulfide bond of F(ab')2 may be cleaved in order to obtain Fab'.
- the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
- Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
- Acid addition salts are e.g. HCI or HBr salts.
- Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion
- R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
- R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1 -C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10- heteroaryl group.
- Figure 1 shows a drug delivery device with a cap attached in accordance with the present disclosure
- Figure 2 shows the drug delivery device of Figure 1 with the cap removed and a dose of 79 units dialed
- Figure 3 shows in an exploded view the components of the drug delivery device of
- Figure 4 shows the outer body of the drug delivery device of Figure 1 ;
- Figure 5a shows the inner body of the drug delivery device of Figure 1 ;
- Figure 5b shows a detail of the inner body of Figure 5a
- Figure 6 shows the cartridge holder of the drug delivery device of Figure 1 ;
- Figure 7a shows a first display member component of the drug delivery device of
- Figure 7b shows a detail of the first display member of Figure 7a
- Figure 8 shows a second display member component of the drug delivery device of Figurel ;
- Figure 9 shows a first driver component of the drug delivery device of Figurel ;
- Figure 10 shows a second driver component of the drug delivery device of Figurel ;
- Figure 1 1 shows a third driver component of the drug delivery device of Figurel ;
- Figure 12 shows the last dose nut of the drug delivery device of Figurel ;
- Figure 13 shows a clutch component of the drug delivery device of Figurel ;
- Figure 14 shows a first clicker component of the drug delivery device of Figurel ;
- Figure 15 shows a second clicker component of the drug delivery device of Figurel ;
- Figure 16 shows the button of the drug delivery device of Figurel ;
- Figure 17 shows a cut-away view of the proximal part of the drug delivery device of
- Figure 18 shows a cut-away view of the proximal part of the drug delivery device of
- Figure 19 shows a cut-away view of the proximal part of the drug delivery device of
- Figure 20a shows a plastic element of the outer housing part
- Figure 20b shows the plastic element and a metal element of the outer housing part during assembling
- Figure 20c shows the plastic element and the metal element of the outer housing part in an assembled state
- Figure 21 a shows a plastic element of a cap
- Figure 21 b shows the plastic element and a metal element of the cap
- Figure 21 c shows a clip element being attached to the cap
- Figure 22a shows a snap feature of the inner housing
- Figure 22b shows the outer housing part being coupled to the inner housing
- Figure 23a shows a metal element of an outer housing part comprising a lug feature
- Figure 23b shows an assembly comprising a metal element comprising a lug feature and a plastic element in a sectional view
- Figure 24a shows a metal element of an outer housing part
- Figure 24b shows an assembly comprising a metal element and a plastic element in a sectional view
- Figure 25a shows a sectional view of a part of the outer housing part comprising a metal element and a plastic element
- Figure 25b shows a further sectional view of the outer housing part of Figure 25A;
- Figure 26 shows an '80Units stop' feature which is arranged on the metal element of the outer housing part
- Figure 27 shows an assembly comprising the metal element of Figure 26.
- Figures 1 and 2 show a drug delivery device 1 in the form of an injection pen. The device has a distal end (lower end in Figure 1 ) and a proximal end (upper end in Figure 1 ). The component parts of the drug delivery device 1 are shown in Figure 3 in more detail.
- the drug delivery device 1 comprises an outer housing part 10, an inner body 20, a piston rod 30, a driver 40, a nut 50, a display member 60, a button 70, a cartridge holder 80 for receiving a cartridge 81 , a clutch 90, a clicker 100, a spring 1 10, a cap 120 and a window insert 130.
- a needle arrangement (not shown) comprising a needle hub and a needle cover may be provided as additional components, which can be
- the piston rod 30 comprises a bearing 31 .
- the driver comprises a distal driver part 41 , a proximal driver part 42 and a coupler 43.
- the display member 60 comprises a number sleeve 61 and a dial sleeve 62.
- the clicker comprises a distal clicker part 101 , a proximal clicker part 102 and a spring 103.
- the outer housing part 10 which is shown in Figure 4, is a generally tubular element having a distal part 1 1 for attaching the inner body 20 and a proximal part, which is provided with a rotational hard stop 12 on its inner surface (not shown) which contact mating faces of the display member 60 when the maximum units (in this example 80U) stop is engaged.
- the end face also serves as the end of dose dispense stop for the button 70, and the bore in the end face centers the display member 60 during both dialing and dispense.
- An aperture 13 is provided for receiving window insert 130.
- the outer body 10 provides the user with a surface to grip and react against during dispense.
- the outer housing part 10 comprises a metal element 132 and a plastic element 133. These elements are shown for example in Figures 20a to 20c.
- Figure 20a shows the plastic element 133 of the outer housing part 10.
- the plastic element 133 is produced by mold flowing or injection molding.
- the plastic element 133 may be made of
- FIG 20b shows the plastic element 133 and the metal element 132 of the outer housing part 10 during assembling.
- the metal element 132 is slid over the plastic element 133.
- the metal element 132 comprises a stop face (not shown), wherein the metal element 132 can be slid over the plastic element 133 until the stop face of the metal element 132 abuts the plastic element 133.
- the stop face of the metal element 132 may be produced by beading one end of the metal element 132. In particular, the beaded end forms the stop face of the metal element 132.
- the metal element 132 is produced by deep drawing.
- the metal element 132 may be made of aluminium or of another metal material.
- the plastic element 133 is coupled to the inner housing 20.
- the inner housing 20 comprises snap features 139.
- the snap features 139 interact with the plastic element 133, thereby fixing the plastic element with respect to the inner housing 20.
- the metal element 132 comprises an aperture 135, which is configured for receiving the window insert 130.
- the outer surface of the plastic element 133 is adapted to the inner surface of the metal element 132. Thereby, the plastic element 133 and the metal element 132 may be accurately fitted together.
- Each of the plastic element 133 and the metal element 132 may have the form of a sleeve.
- FIGs 22a and 22b show snap features 139 of the inner housing 20.
- the outer housing part 10 is coupled to the inner housing 20.
- the snap features 139 are engaged with the plastic element 133 of the outer housing part 10.
- Figure 23a shows the metal element 132 of the outer housing part 10.
- the metal element 132 comprises a radial lug 138.
- the lug feature 138 may comprise one extended lug or a series of smaller lugs.
- the radial lug 138 is folded into the aperture 135.
- the radial lug 138 may be folded along a full perimeter of the aperture 135 or locally as shown.
- the metal element 132 is secured to the plastic element 133, as shown in Figure 23b.
- the radial lug 138 engages with the plastic element 133.
- an axial and rotational position of the metal element 132 with respect to the plastic element 133 is maintained.
- the radial lug 138 is folded into the aperture 135 to a greater depth at one end of the metal element 132, but is not folded into the aperture 135 at the other end.
- a tab 142 (see Figure 23b) of the window insert 130 may be inserted through the aperture 135 under the outer housing part 10. Thereby, the window insert 130 may be secured to the assembly.
- the plastic element 133 is configured to support an underside of the window insert 130.
- the window insert 130 lies on the plastic element 133. Thereby, a risk of scratching a printed lower surface of the window insert 130 is minimized.
- any rotational forces applied to the metal element 132 are transferred via the window insert 130 to the plastic element 133.
- the metal element 132 and the plastic element 133 may be secured with respect to each other by the window insert 130, which is inserted through the aperture 135, as shown in Figure 24b.
- the metal element 132 may be produced without any lug feature.
- the window insert 130 extending through the aperture 135, the metal element 132 and the plastic element 133 may be axially and rotationally fixed with respect to each other.
- the embodiment according to Figures 24a and 24b has the advantage that it is simpler to manufacture without the folded lug feature 138.
- the plastic element 133 and the metal element 132 may be coupled to each other by press fitting.
- one or both of the plastic element 133 and the metal element 132 may comprise a feature which may fix the elements together by snap fitting.
- the plastic element 133 and the metal element 132 may be fix together by bonding with an adhesive or via application of heat to activate a bonding agent or to fuse the parts together.
- the plastic element 133 may comprise a protrusion (not shown).
- the protrusion may be located at an axial end of the plastic element 133.
- the protrusion may extend in a radial outward direction.
- the metal element 132 may extend over the plastic element 133 until it abuts the protrusion. Thereby, an axial position of the metal element 132 with respect to the plastic element 133 may be defined.
- the protrusion of the plastic element 133 may comprise a nose which extends in a longitudinal direction.
- the nose may be configured to engage with a corresponding recess of the metal element 132.
- a rotational position of the metal element 132 with respect to the plastic element 132 may be defined.
- the metal element may have a flange at the proximal end which partially encloses the plastic element so as to restrain it axially, see Fig 25a and 25b.
- the plastic element 133 and the metal element 132 form a functional unit.
- the plastic element 133 and the metal element 132 may be releasably or permanently coupled to each other.
- the cap 120 comprises, as does the outer housing part 10, a metal element 150 and a plastic element 131 .
- the metal element 150 and the plastic element 131 of the cap are shown in Figures 21 a to 21 c.
- Figure 21 a shows a plastic element 131 of the cap 120.
- Figure 21 b shows the metal element 150 attached to the plastic element 131 of the cap 120.
- the metal element 150 and the plastic element 131 of the cap 120 are similar to the metal element 132 and the plastic element 133 of the outer housing part 10. Therefore, it is referred to the description above.
- the plastic element 131 and the metal element 150 of the cap 120 have a slightly different shape than the corresponding elements of the outer housing part 10.
- the metal element 150 has an end face 137, which is inclined to a longitudinal axis of the assembly.
- the end face 137 may be inclined to a longitudinal axis of the cap for about 60° to 80°.
- the end face 137 is inclined for design reasons.
- the cap 120 comprises a clip element 134.
- the clip element 134 is inserted into an aperture 135 of the cap 120.
- the clip element 134 is fixed to the cap 120 for example by snap fitting.
- the clip element 134 being attached to the cap 120 is shown in Figure 21 c.
- the clip element 134 may be configured to hold the metal element 130 and the plastic element 131 in a fixed position with respect to each other.
- the inner body 20 is a generally tubular element having different diameter regions. As can be seen in Figures 17 to 19, the inner body 20 is received in the outer body 10 and permanently fixed therein to prevent any relative movement of the inner body 20 with respect to the outer body 10.
- the inner body has the functions to house the drive mechanism within, guiding the clickers and the last dose nut 50 via internal splines, to provide an internal thread through which the piston rod 30 (lead screw) is driven, to support and guide the number sleeve 61 and the dial sleeve 62 on an external thread form, to secure the cartridge holder 80 and to secure the outer body 10 and the window insert 130.
- the outermost diameter of the inner body 20 also forms part of the visual design and remains visible when the cap 120 is secured to the cartridge holder 80 as a ring separating the cap 120 from the outer body 10.
- This visible ring also has depressions which align with the cap snap features on the cartridge holder 80 to indicate that the cartridge holder has been correctly fitted.
- An external thread 21 is provided on the outer surface of the inner body 20.
- splines 22 (Figure 5b) are provided on the inner surface of the inner body 20. These internal splines 22 guide the clicker 100 axially during both dialing and dispense and also prevent the last dose nut 50 from rotating. Some of the splines may be wider to ensure correct rotational assembly of the internal components, and these wider splines may have a stepped entry and angled surface to encourage the last dose nut 50 to rotate up against the stop face on the distal drive sleeve 41 during assembly.
- a window retention nose 24 retains the window insert 130 when the outer body 10 and window insert 130 assembly is axially inserted onto the inner body 20.
- Two diametrically opposite stop faces 25 define the rotational end position for the number sleeve 61 . This end position is the end of dose detent position for the minimum dose (0U).
- the piston rod 30 is an elongate element having two external threads 32, 33 with opposite hand which overlap each other. One of these threads 32 engages the inner thread of the inner body 20.
- a disk-like bearing 31 is provided at the distal end of the piston rod 30.
- the bearing 31 may be a separate component as shown in Figure 3 or may be attached to the piston rod 30 as a one-piece component via a predetermined breaking point.
- the piston rod 30 transfers the dispense load from the driver 40 to the bearing 31 , creating a mechanical advantage greater than 1 :1 by converting the torque generated on the piston rod 30 by the driver 40 thread interface into additional axial load as the piston rod passes through the thread in the inner body 20.
- the piston rod 30 is reset by pressing on the bearing 31 and this in turn rotates the piston rod back into the inner body 20. This disengages and then rotates the distal drive sleeve 41 , resetting the last dose nut 50 back to its starting position on the distal drive sleeve 41 .
- the driver 40 is a generally tubular element having in the embodiment shown in the Figures three components which are depicted in Figures 9 to 1 1 in more detail.
- the distal drive sleeve 41 engages with the piston rod thread 33 to drive the piston rod 30 through the inner body 20 during dose delivery.
- the distal drive sleeve 41 is also permanently connected to the coupler 43 which in turn is releasably engaged through reset clutch features to the proximal drive sleeve 42.
- the two halves of the drive sleeve are rotationally and axially connected during dialing and dispense, but are de-coupled rotationally during device reset so that they can rotate relative to each other.
- the external thread 44 engages with the last dose nut 50.
- the thread form has three stages, a shallow first stage (left hand side in Figure 9) over which the nut 50 travels to count the majority of the units dialed, a fast stage over which the last dose nut moves rapidly axially prior to engaging the stop faces, and a final shallow section which ensures that when the stop faces have engaged, the axial restraint on the nut 50 extends over a reasonable length of thread form.
- Four equi-spaced stop faces 45 engage with mating stop faces 51 on the last dose nut 50 to limit the number of units that can be dialed.
- Splines 46 are provided at the proximal end of distal drive sleeve 41 to transfer torque from or to the coupler 43, which may be snapped on the distal drive sleeve 41 .
- the proximal drive sleeve 42 shown in Figure 10 supports the clicker components 100 and the clutch 90 and transfers rotational movement from the dose button 90 to the coupler 42 and distal drive sleeve 41 .
- Teeth features 47 located at the distal end of proximal drive sleeve 42 engage with the reset clutch features on the coupler 43 to connect both halves of the drive sleeve during dialing and dispense. During reset these teeth 47 disengage.
- proximal drive sleeve 42 engaging with distal clicker part 101 , preventing relative rotation during dialing and dispense.
- the proximal portion of proximal drive sleeve 42 has four arms or fingers 48.
- a hooklike bearing surface 49 exists on the underside (as seen in Figure 10) of flange segments on the end of the flexible fingers 48.
- the flexible fingers 48 are separated with gaps or slots that make space for the button 70 to snap to the clutch 90 and also enable these fingers to flex inwards during assembly of the proximal drive sleeve 42 to the dial sleeve 62.
- the hooks 49 retain the proximal drive sleeve 42 relative to the dial sleeve 62 under the reaction force from the spring 103.
- the button 70 depresses the spring 103 via the clutch 90 and the clicker components and this spring 103 is reacted through the coupler 43 to the proximal drive sleeve 42 which then through these bearing surfaces applies axial load to the dial sleeve 62.
- This axial load drives the dial sleeve 62 and hence number sleeve 61 along the helical thread of the inner body 20, back into the body of the device, until the 0U stop faces on the number sleeve 61 contact the inner body 20.
- the coupler 43 shown in Figure 1 1 rotationally couples the two halves of the drive sleeve together during dialing and dispense, whilst allowing them to de-couple during reset.
- the coupler 43 has to also transfer the last dose protection stop load from the proximal drive sleeve 42 to the distal drive sleeve 41 .
- Two sets of teeth are provided in the coupler 43 for engaging teeth 46 and teeth 47, respectively.
- the coupler 43 is snapped onto distal drive sleeve 41 allowing limited relative axial movement with respect to the proximal drive sleeve 42.
- the nut 50 is provided between the inner body 20 and the distal drive sleeve 41 of driver 40. Stop faces 51 are located on the proximal face of last dose nut 50 to limit the number of units that can be dialed if the stop faces 51 contact stops 45 of distal drive sleeve 41 .
- the function of the last dose nut 50 is to prevent the user from dialing beyond a finite amount. This limit is based on the dispensable volume of the cartridge 81 and when reached, the user must replace the cartridge 81 and reset the device.
- External ribs 52 of the nut 50 engage splines 22 of inner body 20.
- An internal thread 53 of the nut engages the external thread 44 of distal drive sleeve 41 .
- the display member 60 is a generally tubular element which is composed of number sleeve 61 and dial sleeve 62 which are snapped together during assembly to axially and rotationally constrain these two components, which thus act as a single part.
- the main functions of the number sleeve 61 depicted in Figure 8 are to provide a surface onto which dose numbers can be printed to display the dialed dose, to guide the helical path of the internal mechanism during dialing to follow the helical thread form on the piston rod 30 when threaded to the inner body 20 and to attach to the dial sleeve 62.
- the number sleeve 61 is designed to be fully enclosed in the outer body 10 during dialing and dispense and therefore only the dialed dose is visible to the user through the window aperture.
- the number sleeve has a 0U (minimum dose) stop face 63 to limit its travel when dialed in but the 80U (maximum dose) stop faces that limit the dialed out condition are located on the dial sleeve 62. At the end of each dispense stroke, this stop face 63 engages with mating surface 25 on the inner body 20 to limit the rotational position of the number sleeve 61 .
- Figures 25a and 25b each show a cross section of the metal element 132 and the plastic element 133 of the outer housing part 10 showing a stop feature 140.
- the stop feature 140 may be an '80Units stop' feature.
- the stop feature 140 may be a rotational stop.
- the stop feature 140 is arranged on the plastic element.
- Figure 26 shows an embodiment wherein the stop feature 140 is comprised by the metal element 132 of the outer housing part 10.
- the stop feature 140 is formed as a series of lug features 141 .
- the folded lug features 141 form a bearing surface for the dial sleeve 62.
- This bearing is advantageously of low friction to minimize dispense force and to avoid scratching the dial sleeve 62.
- the advantage of the embodiment shown in Figure 26 is that the plastic element is much shorter and is therefore easier and cheaper to mold.
- the length of the plastic element 133 is about one third of the length of the metal element.
- an '80Units torque' is transferred via the inner housing 20 to the plastic element 133 if the user counteracts this torque by holding the cartridge holder.
- Figure 27 shows an assembly with the dial sleeve 62 and the number sleeve 61 and a part of the metal element 132 comprising the stop feature 140, in particular the '80Units stop' feature.
- the main surface of the metal element 132 is cut away for clarity reasons.
- the assembly is shown in a state where an '80Units stop' feature on the dial sleeve 62 is engaged with the stop feature 140 of the metal element.
- a rotational stop is provided for the dial sleeve 62.
- a helical drive face 64 forms a thread that guides the number sleeve 61 during dialing and dispense to follow the helical path 21 on the inner body.
- the dial sleeve 62 is assembled to the number sleeve 61 such that once assembled, no relative movement is allowed.
- the parts are made as separate components to enable both molding and assembly.
- the number sleeve 61 is preferably white to give contrast for the e.g. black dose numbers
- the dial sleeve 62 color can be chosen to suit the aesthetics or perhaps to distinguish the drug type.
- the dial sleeve 62 has internal clutch features 65 that engage with the clutch component 90 during dialing and disengage from the clutch during dispense. These clutch features 65 rotationally lock the dial sleeve 62 to the clutch 90 during dialing and when the 0U and 80U stops are engaged. When the button 70 is depressed these clutch features disengage to allow the clutch 90 and drive mechanism to move axially whilst the dial sleeve 62 and number sleeve 61 spin back to the 0U start position.
- the dial sleeve 62 rotates out during dialing through its engagement with the clutch 90 and number sleeve 61 , and rotates back in during dispense under the axial force applied by the proximal drive sleeve 42 to a flange-like bearing face 66 on the end of the dial sleeve.
- This bearing face 66 engages with the flexible arms 48 of the proximal drive sleeve 42 during dispense.
- Two diametrically opposite faces 67 engage with the outer body 10 when the maximum dose (e.g. 80U) has been dialed, forming the maximum dose stop faces.
- a ratchet arm 68 engages with ratchet features on the button 70 (dose dial grip) to provide audible feedback during dispense, giving one click per unit delivered. Further, this prevents the user from gripping and rotating the number sleeve 61 outwards from a partially dialed out position whilst holding the button 70 pressed in. This would back wind the piston rod 30 which would result in an under dose on the subsequent dialed dose. It may further strengthen the 0U stop.
- the button 70 which is shown in Figure 16 serves as a dose dial grip and is retained by the clutch 90 to transfer the actions of the user to the clutch. It also carries ratchet teeth 71 that engage the ratchet arm 68 on the dial sleeve 62, which serves as the dispensing clicker giving audible feedback (ratchet clicks), and an end face 72 which serves as the dose completion stop face with the outer body 10. This end face 72 thus serves to define the end position during dispense when it contacts the outer body 10 to provide a very positive stop improving dose accuracy.
- a central sleeve-like portion of button 70 is provided with four arms 73 having hook-like snap features 74 at their respective distal ends.
- the arms 73 form splined surfaces engaging with the clutch 90 to transfer torque from the button 70 through the clutch to the dial sleeve 62 and proximal drive sleeve 42.
- the snap features 74 engage apertures in the clutch 90 and are designed with angled undercut faces to maintain engagement when an axial load is applied to pull the button 70 out of the pen body 10.
- the space between arms 73 defines pockets giving clearance for the flexible arms 48 of proximal drive sleeve 42 to slide freely relative to the button 70 and clutch 90 when the button 70 is depressed and released during dose dispense.
- the cartridge holder 80 attaches to the inner body 20 with a bayonet connection 82 and houses the glass ampoule or cartridge 81 containing the medication to be dispensed.
- the cartridge holder 80 includes an aperture 83 in the rear face (as seen in Figure 6) which if gripped by the user prevents the ampoule from falling out when the cartridge holder is removed from the inner body 20.
- the front face is printed with a dose number scale.
- the threaded distal end 84 is used to attach disposable pen needles.
- a tubular clutch 90 is provided between the display member 60 and the button 70.
- the clutch is fixed relative to and retains the button 70 and together they travel axially relative to the proximal drive sleeve 42 when the button 70 is depressed during dispense, disengaging the clutch teeth from the dial sleeve 62. It also transfers torque from the button to the proximal drive sleeve 42, and the dialing and 0U/80U stop loads from the button via the clutch teeth to the dial sleeve and number sleeve.
- Drive sleeve splines 91 provided on an inner surface of the clutch engage with the proximal drive sleeve 42.
- clutch biasing teeth 92 are provided which mate with similar teeth on the proximal clicker part 102 to ensure that in the button out position (dialed dose) the clutch is locked in rotation to the proximal clicker part 102 under the biasing action of the clutch spring 103.
- the teeth 92 are shallow in height to prevent the proximal clicker part 102 from engaging with splines on the proximal drive sleeve 42 during dialing.
- Four snap apertures 93 serve to retain the snap features 74 of button 70.
- the clutch has splines 94 which at the end of dispense with the button 70 depressed lock to the inner body 20 to prevent the user from rotating the button 70 below the 0U position.
- Clutch teeth 95 engage with clutch teeth 65 of the dial sleeve to rotationally couple the button 70 via the clutch to the number sleeve 61 .
- the clicker 100 comprises a distal clicker part 101 , a proximal clicker part 102 and a spring 103.
- the clutch spring 103 serves to bias the button 70 out so that at the end of a dose the button 70 pops out, re-engaging the clutch 90 with the dial sleeve 62 ready for dialing.
- the clicker components provides the spring force for the clicker components to act as clickers and also as detent positions for the number sleeve 61 .
- it holds the two halves of the drive sleeves 41 , 42 in rotational engagement during dialing and dispense, whilst allowing them to disengage during device reset.
- the distal clicker part 101 is permanently splined to the proximal drive sleeve 42 and engages with the proximal clicker part 102 which in turn is splined to the inner body 20.
- the two clickers 101 , 102 rotate relative to each other under the compression force of the clutch spring 103. This force combined with the clicker teeth formed on the end face of each clicker provides the clicks and also the detent dialing positions.
- the two clickers 101 , 102 are pressed together under the dispense load and therefore prevent relative rotation between the proximal drive sleeve 42 and inner body 20, driving the piston rod forwards to deliver the dose.
- the splines 104 on the inner bore rotationally couple the distal clicker part 101 to the proximal drive sleeve 42 at all times, but allow free axial movement when the button 70 is depressed during dispense and when the two clickers ride over each other during dialing.
- the profile of the clicker teeth 105, 106 on both distal clicker part 101 and proximal clicker part 102 are identical and ride over each other under the compressive load from the spring 103 during dialing.
- the proximal clicker part 102 is permanently splined to the inner body 20 by external splines 107 which prevent relative rotation with the inner body during both dialing and dispense, providing clicks during dialing and locking the proximal drive sleeve 42 in rotation during dispense. Additional cylindrically shaped splines 108 also couple the proximal clicker part 102 rotationally to the proximal drive sleeve 42 when the button 70 is depressed, this preventing the user from dialing past 80 units with the button depressed.
- Proximal clicker part 102 in addition to the primary clicker teeth 106, has clutch biasing teeth 109 on the opposite end face. These teeth mate with similar teeth 92 on the clutch to ensure that in the button out position (dialed dose) the clutch is locked in rotation to the proximal clicker part 102 under the biasing action of clutch spring 103.
- the cartridge bias spring 1 10 is assembled as two components one after the other, the lower first and the upper second.
- the spring combination serves to apply an end load to the cartridge 81 at extremes of tolerance so as to bias it forwards onto the end face of the ferrule in the cartridge holder 80. This ensures that when the user removes and attaches a needle, the friction between the needle cannula and septum of the cartridge does not move the cartridge 81 axially relative to the cartridge holder 80.
- the bias spring 1 10 also acts to provide a force against which the user has to connect the cartridge holder 80 and this may add to the tactile feedback of this bayonet joint.
- the spring 100 also serves to eject the cartridge holder 80 if the cartridge holder is not rotated into a secure position, highlighting this error to the user.
- the cap 120 serves to protect the cartridge holder 80 from damage and the cartridge 81 itself from dust dirt ingress on to the area around the septum.
- the cap is designed to accommodate a standard pen injector needle.
- the window insert 130 may include a lens to magnify the dose numbers e.g. by approximately 25% from their printed size.
- the window insert 130 may be back printed to protect the printed surface from abrasion and also to maximize the light entering through the window aperture, giving uniform illumination of the dose numbers and white area around these numbers. Arrows may be printed adjacent to the window aperture that indicate the dose dialed.
- a user has to select a dose.
- the display member 60 indicates the number of doses dialed to the user.
- the number of dialed units can be viewed through the dose window 130 in the outer body 10. Due to the threaded engagement between the display member 60 and the inner body 20 rotation of the button 70 in a clockwise fashion causes the display member 60 to wind out of the device and incrementally count the number of units to be delivered.
- Figure 18 shows an intermediate stage of dialing (e.g. 7 of 80 units).
- button 70 During dose setting button 70, driver 40 and display member 60 are rotationally locked together via clutch 90. Further, button 70, driver 40 and display member 60 are axially coupled. Thus, these three components wind out of the outer housing 10 during dose setting. Clockwise rotation of the button 70 causes the driver 40 to rotate and in doing so it advances along the piston rod 30 which remains fixed throughout dialing.
- the clicker arrangement 100 provides tactile and audible feedback to the user when dialing doses. At the maximum settable dose of 80 units, the stop features 12 and 67 engage to prevent further dialing.
- the last dose nut 50 provides the function of counting the number of dispensed units. The nut 50 locks the device at the end of cartridge life and as such no more drug can be dialed by the user.
- the last dose nut 50 and the driver 40 are connected via a threaded interface as explained above. Further, the last dose nut 50 is assembled into splines 22 such that the nut 50 and the inner body 20 are rotationally locked together (at all times). Rotation of the driver 40 during dialing causes the nut 50 to advance along the thread 44. The nut 50 is free to slide axially within the inner body 20 at all times which allows advancement of the nut. The change in pitch of thread 44 shown in Figure 9 towards the final doses axially accelerates the advancement of the nut 50 towards the end of cartridge life lockout condition. At the end of life condition, the stop features 51 of the last dose nut 50 contact the corresponding features 45 on the driver 40.
- the device 1 With the desired dose dialed, the device 1 is ready for dose dispensing. This basically requires pushing button 70 which will result in a disengagement of the clutch 90 from dial sleeve 62 thus allowing relative rotation between the display member 60 and the button 70.
- the driver 40 and the button 70 are rotationally locked together by engagement of arms 73 and fingers 48 and by splines 91 engaging corresponding splines on proximal drive sleeve 42.
- button 70 and driver 40 are rotationally locked together with the button 70, the driver 40 and the display member 60 still being axially coupled.
- the dose button 70 and clutch 90 are moved axially relative to the mechanism compressing the clutch spring 103. Because the proximal clicker part 102 is splined to the inner body 20 and the axial load passing through the clicker teeth 105, 106 locks the distal clicker part 101 in rotation to the proximal clicker part 102, the mechanism is forced to move axially whilst the dial sleeve 62 and number sleeve 61 are free to spin back into the outer housing 10. The interaction of mating threads between the piston rod 30, driver 40 and inner body 20 delivers a mechanical advantage of 2:1 .
- axially advancing driver 40 causes the piston rod 30 to rotate which due to the threaded engagement of piston rod 30 with the inner body 20 advances the piston rod.
- dispense clicker 68, 71 is active which involves button 70 and display member 60.
- the dispense clicker provides primarily audible feedback to the user that drug is being dispensed.
- Resetting the device starts with removal of the cartridge holder 80 and replacing an empty cartridge with a full cartridge 81 .
- the bung of the new cartridge contacts bearing 31 , thus pushing piston rod 30 back into the housing.
- the piston rod 30 screws into the inner body 20, thereby axially disengaging the coupler 43 from the proximal drive sleeve 42 against the biasing force of spring 103.
- the coupler 43 is free to start rotating together with distal drive sleeve 41 and continues to do so as the cartridge holder 80 is moved axially into engagement with the inner body 20.
- the distal drive sleeve 41 rotates with respect to the proximal drive sleeve 42 which is still rotationally constrained in inner body 20 as clicker parts 101 and 102 are pressed together by compressed spring 103.
- last dose nut 50 is reset to its (distal) start position. Coupling the cartridge holder 80 to inner body 20 backs off the mechanism due to the bayonet structure 23 allowing re-engagement of the proximal drive sleeve 42 with coupler 43 and thus the distal drive sleeve 41 .
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201480047825.7A CN105492046B (en) | 2013-08-29 | 2014-08-26 | The shell and lid of injection device for being partially fabricated by outer metal portion and Inner plastic |
KR1020167007464A KR102461754B1 (en) | 2013-08-29 | 2014-08-26 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
BR112016003310-8A BR112016003310B1 (en) | 2013-08-29 | 2014-08-26 | DRUG APPLICATION DEVICE |
EP14755665.8A EP3038676A1 (en) | 2013-08-29 | 2014-08-26 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
RU2016111378A RU2689762C2 (en) | 2013-08-29 | 2014-08-26 | Shell and cap for injection device made of outer metal part and inner plastic part |
US14/914,472 US10668218B2 (en) | 2013-08-29 | 2014-08-26 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
AU2014314290A AU2014314290B2 (en) | 2013-08-29 | 2014-08-26 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
CA2921926A CA2921926A1 (en) | 2013-08-29 | 2014-08-26 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
MX2016002588A MX2016002588A (en) | 2013-08-29 | 2014-08-26 | Housing and cap for an injection device made of an outer metal part and an inner plastic part. |
JP2016537254A JP6764786B2 (en) | 2013-08-29 | 2014-08-26 | Housings and caps for injection devices made of outer metal and inner plastic parts |
IL243906A IL243906B (en) | 2013-08-29 | 2016-02-02 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
HK16111379.0A HK1223048A1 (en) | 2013-08-29 | 2016-09-29 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13182221.5 | 2013-08-29 | ||
EP13182221 | 2013-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015028441A1 true WO2015028441A1 (en) | 2015-03-05 |
Family
ID=49054427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/068023 WO2015028441A1 (en) | 2013-08-29 | 2014-08-26 | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
Country Status (15)
Country | Link |
---|---|
US (1) | US10668218B2 (en) |
EP (1) | EP3038676A1 (en) |
JP (1) | JP6764786B2 (en) |
KR (1) | KR102461754B1 (en) |
CN (1) | CN105492046B (en) |
AR (1) | AR097469A1 (en) |
AU (1) | AU2014314290B2 (en) |
BR (1) | BR112016003310B1 (en) |
CA (1) | CA2921926A1 (en) |
HK (1) | HK1223048A1 (en) |
IL (1) | IL243906B (en) |
MX (1) | MX2016002588A (en) |
RU (1) | RU2689762C2 (en) |
TW (1) | TWI655012B (en) |
WO (1) | WO2015028441A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017207504A1 (en) * | 2016-05-31 | 2017-12-07 | Sanofi-Aventis Deutschland Gmbh | Cap assembly for a drug delivery device and method for assembling a cap assembly |
KR20190013941A (en) * | 2016-05-31 | 2019-02-11 | 사노피-아벤티스 도이칠란트 게엠베하 | Button for drug delivery device and method for assembling button for drug delivery device |
US10668218B2 (en) | 2013-08-29 | 2020-06-02 | Sanofi-Aventis Deutschland Gmbh | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
WO2023078855A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Electronic module, drug delivery device and method for operating an electronic module |
WO2023078860A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Drug delivery device, drug reservoir unit and set |
WO2023078852A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Drug delivery device, drug reservoir unit and set |
WO2023078845A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Drug delivery device |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101993597B1 (en) * | 2017-03-24 | 2019-06-27 | 장상훈 | Syringe |
CN207545570U (en) * | 2017-05-08 | 2018-06-29 | 甘肃成纪生物药业有限公司 | A kind of injection pen |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1561832A1 (en) * | 1967-04-01 | 1970-04-02 | Hennefer Schreibwaren Fabrik R | Push-in cap for pens |
WO1988008725A1 (en) * | 1987-05-08 | 1988-11-17 | Wilhelm Haselmeier Gmbh + Co. | Injection device with a loading element and a second setting element |
US20040015038A1 (en) * | 2000-09-01 | 2004-01-22 | Pierre-Marie Lemer | Device for protecting a syringe, in particular for a syringe used for injecting radioactive product (s) |
US20070265579A1 (en) * | 2006-05-10 | 2007-11-15 | Gennady Kleyman | Dental syringe |
EP1603611B1 (en) * | 2003-03-03 | 2008-05-07 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for drug delivery device |
CN201097144Y (en) * | 2007-08-17 | 2008-08-06 | 深圳市宝安区新安安泰时计制品厂 | Watch |
WO2008128645A1 (en) * | 2007-04-18 | 2008-10-30 | Sanofi-Aventis Deutschland Gmbh | Injection device for delivering a medication |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US533575A (en) | 1895-02-05 | wilkens | ||
GB8713810D0 (en) | 1987-06-12 | 1987-07-15 | Hypoguard Uk Ltd | Measured dose dispensing device |
US5226895A (en) | 1989-06-05 | 1993-07-13 | Eli Lilly And Company | Multiple dose injection pen |
GB9007113D0 (en) | 1990-03-29 | 1990-05-30 | Sams Bernard | Dispensing device |
US5226896A (en) | 1990-04-04 | 1993-07-13 | Eli Lilly And Company | Dose indicating injection pen |
AU641206B2 (en) | 1991-01-22 | 1993-09-16 | Eli Lilly And Company | Multiple dose injection pen |
EP0525525B1 (en) | 1991-07-24 | 1995-05-03 | Medico Development Investment Company | Injector |
DK175491D0 (en) | 1991-10-18 | 1991-10-18 | Novo Nordisk As | APPARATUS |
US5279585A (en) | 1992-02-04 | 1994-01-18 | Becton, Dickinson And Company | Medication delivery pen having improved dose delivery features |
US5271527A (en) | 1992-04-02 | 1993-12-21 | Habley Medical Technology Corporation | Reusable pharmaceutical dispenser with full stroke indicator |
US5300041A (en) | 1992-06-01 | 1994-04-05 | Habley Medical Technology Corporation | Dose setting and repeating syringe |
US5391157A (en) | 1992-10-20 | 1995-02-21 | Eli Lilly And Company | End of dose indicator |
US5378233A (en) | 1992-11-18 | 1995-01-03 | Habley Medical Technology Corporation | Selected dose pharmaceutical dispenser |
US5320609A (en) | 1992-12-07 | 1994-06-14 | Habley Medical Technology Corporation | Automatic pharmaceutical dispensing syringe |
FR2701211B1 (en) | 1993-02-08 | 1995-05-24 | Aguettant Lab | DOSING INSTRUMENT, ESPECIALLY INJECTION |
US5383865A (en) | 1993-03-15 | 1995-01-24 | Eli Lilly And Company | Medication dispensing device |
ZA941881B (en) | 1993-04-02 | 1995-09-18 | Lilly Co Eli | Manifold medication injection apparatus and method |
US5582598A (en) | 1994-09-19 | 1996-12-10 | Becton Dickinson And Company | Medication delivery pen with variable increment dose scale |
CA2213682C (en) * | 1995-03-07 | 2009-10-06 | Eli Lilly And Company | Recyclable medication dispensing device |
AU1860697A (en) | 1995-09-08 | 1997-07-28 | Visionary Medical Products Corporation | Pen-type injector drive mechanism |
US5688251A (en) | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
US5674204A (en) | 1995-09-19 | 1997-10-07 | Becton Dickinson And Company | Medication delivery pen cap actuated dose delivery clutch |
US5851079A (en) | 1996-10-25 | 1998-12-22 | The Procter & Gamble Company | Simplified undirectional twist-up dispensing device with incremental dosing |
DE19730999C1 (en) | 1997-07-18 | 1998-12-10 | Disetronic Licensing Ag | Injection pen dosing selected volume of fluid, especially insulin |
US5957896A (en) | 1997-08-11 | 1999-09-28 | Becton, Dickinson And Company | Medication delivery pen |
US6610042B2 (en) | 1997-12-05 | 2003-08-26 | Felton Medical, Inc. | Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof |
ES2153711T3 (en) | 1998-01-30 | 2001-03-01 | Novo Nordisk As | INJECTION SYRINGE. |
US6221053B1 (en) | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
US5961495A (en) | 1998-02-20 | 1999-10-05 | Becton, Dickinson And Company | Medication delivery pen having a priming mechanism |
US6248095B1 (en) | 1998-02-23 | 2001-06-19 | Becton, Dickinson And Company | Low-cost medication delivery pen |
DE19900827C1 (en) | 1999-01-12 | 2000-08-17 | Disetronic Licensing Ag | Device for the dosed administration of an injectable product |
DE19900792C1 (en) | 1999-01-12 | 2000-06-15 | Disetronic Licensing Ag | Injection unit forming part of e.g. pen-type self-injection syringe has continuous dosing stop in spiral form with constant pitch ensuring close fine control and accuracy in use |
DE29900482U1 (en) | 1999-01-14 | 2000-08-31 | Medico Development Investment Co., Ascona | Injection device |
SE9901366D0 (en) | 1999-04-16 | 1999-04-16 | Pharmacia & Upjohn Ab | Injector device and method for its operation |
ES2258469T3 (en) | 1999-08-05 | 2006-09-01 | Becton Dickinson And Company | MEDICATION ADMINISTRATION PENCIL. |
JP2001063283A (en) | 1999-08-30 | 2001-03-13 | Pentel Corp | Composite writing instrument |
GB0007071D0 (en) | 2000-03-24 | 2000-05-17 | Sams Bernard | One-way clutch mechanisms and injector devices |
US6663602B2 (en) | 2000-06-16 | 2003-12-16 | Novo Nordisk A/S | Injection device |
US6432087B1 (en) | 2000-07-31 | 2002-08-13 | Becton, Dickinson And Company | Hypodermic syringe with selectively retractable needle |
NZ539404A (en) | 2000-10-09 | 2007-05-31 | Lilly Co Eli | Pen device for administration of parathyroid hormone |
US6899699B2 (en) | 2001-01-05 | 2005-05-31 | Novo Nordisk A/S | Automatic injection device with reset feature |
EP1776975B1 (en) | 2001-05-16 | 2011-06-22 | Eli Lilly & Company | Medication injector apparatus with drive assembly that facilitates reset |
WO2003080160A1 (en) | 2002-03-18 | 2003-10-02 | Eli Lilly And Company | Medication dispensing apparatus with gear set for mechanical advantage |
EP1545663B1 (en) | 2002-10-01 | 2006-08-30 | Becton Dickinson and Company | Medication delivery pen |
US20040162517A1 (en) * | 2002-12-04 | 2004-08-19 | Otto Furst | Needleless hydpodermic injection device with non-electric ignition means |
GB0304823D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
US6932794B2 (en) | 2003-04-03 | 2005-08-23 | Becton, Dickinson And Company | Medication delivery pen |
EP1541185A1 (en) | 2003-12-08 | 2005-06-15 | Novo Nordisk A/S | Automatic syringe with priming mechanism |
US7201740B2 (en) * | 2004-07-01 | 2007-04-10 | Becton, Dickinson And Company | Forward-shielding blood collection set |
DE102004063645A1 (en) | 2004-12-31 | 2006-07-20 | Tecpharma Licensing Ag | Device for metered administration of a fluid product with decoupling for a container change |
JP4970286B2 (en) | 2005-02-11 | 2012-07-04 | ノボ・ノルデイスク・エー/エス | Injection device |
TWI265036B (en) | 2005-04-29 | 2006-11-01 | Guo-Ming Huang | Safety injector and method of operating the same |
US8147460B2 (en) * | 2006-01-31 | 2012-04-03 | Roche Diagnostics International Ag | Administering device with a multi-component injection-moulded housing |
CA2639320C (en) * | 2007-09-07 | 2016-10-25 | Becton, Dickinson And Company | Pen-needle assembly for preventing under-torquing and over-torquing of pen-needle |
US8011507B2 (en) * | 2007-10-24 | 2011-09-06 | Bemis Manufacturing Company | Methods and apparatus for collecting and disposing of sharps |
US8267900B2 (en) | 2008-05-02 | 2012-09-18 | Sanofi-Aventis Deutschland Gmbh | Medication delivery device |
US8647309B2 (en) * | 2008-05-02 | 2014-02-11 | Sanofi-Aventis Deutschland Gmbh | Medication delivery device |
WO2010112558A1 (en) * | 2009-03-31 | 2010-10-07 | Sanofi-Aventis Deutschland Gmbh | Drug delivery device with dose indication window |
SG175279A1 (en) * | 2009-04-29 | 2011-11-28 | Abbott Biotech Ltd | Automatic injection device |
PL214940B1 (en) | 2009-07-31 | 2013-09-30 | Lozano Platonoff Alberto | Indication mechanism of an automatic applicator, especially for insulin |
US9526846B2 (en) * | 2009-08-19 | 2016-12-27 | Safety Syringes, Inc. | Patient-contact activated needle stick safety device |
US9039655B2 (en) * | 2009-11-06 | 2015-05-26 | Crisi Medical Systems, Inc. | Medication injection site and data collection system |
WO2011124633A1 (en) | 2010-04-09 | 2011-10-13 | Sanofi-Aventis Deutschland Gmbh | Method and system for differentiating drug delivery devices |
US9522368B2 (en) * | 2010-10-26 | 2016-12-20 | Kettenbach Gmbh & Co. | Double cartridge, mixer therefor and combination of double cartridge and mixer |
US8663407B2 (en) | 2010-11-17 | 2014-03-04 | 3M Innovative Properties Company | Isobutylene (Co)polymeric adhesive composition |
GB201020475D0 (en) * | 2010-12-02 | 2011-01-19 | Oval Medical Technologies Ltd | Delivery mechanism for an autoinjector |
EP2495003B1 (en) * | 2011-03-04 | 2014-11-19 | 3M Innovative Properties Co. | Plunger for a syringe and method of making such a plunger |
CN106955394B (en) * | 2011-09-02 | 2020-02-04 | 尤尼特拉克特注射器控股有限公司 | Drive mechanism for a drug delivery pump with integrated status indication |
CA2852187A1 (en) * | 2011-10-17 | 2013-04-25 | Shl Group Ab | Device for removing delivery member shields |
US9033912B2 (en) * | 2012-03-28 | 2015-05-19 | Warsaw Orthopedic, Inc. | Drug delivery system |
GB201212190D0 (en) * | 2012-07-09 | 2012-08-22 | Oval Medical Technologies Ltd | Injector device with mechanism for preventing accidental activation |
US12029885B2 (en) * | 2012-11-13 | 2024-07-09 | IN.TOOL ApS | Protective cap for a device |
FR2999436B1 (en) * | 2012-12-14 | 2016-02-05 | Transformation Des Elastomeres A Usages Medicaux Et Ind Soc D | NEEDLE PROTECTION SYSTEM OF AN INJECTION DEVICE. |
WO2014165142A1 (en) * | 2013-03-13 | 2014-10-09 | Benjamin Newton | Multiple dosage injector with rotating screw dosage system |
DK2978478T3 (en) * | 2013-03-25 | 2021-08-02 | Shl Medical Ag | PROTECTIVE CAP FOR A DRUG DELIVERY DEVICE |
CN104602741B (en) * | 2013-03-26 | 2018-10-26 | 泰尔茂株式会社 | Spring caps and the syringe assembly for having the spring caps |
GB201307385D0 (en) * | 2013-04-24 | 2013-06-05 | Star Syringe Ltd | Syringes |
GB201314381D0 (en) * | 2013-08-12 | 2013-09-25 | Ucb Pharma Sa | Injector |
ES2881077T3 (en) * | 2013-08-29 | 2021-11-26 | Sanofi Aventis Deutschland | Cap assembly for a drug delivery device and drug delivery device |
AU2014314290B2 (en) | 2013-08-29 | 2018-11-08 | Sanofi-Aventis Deutschland Gmbh | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
-
2014
- 2014-08-26 AU AU2014314290A patent/AU2014314290B2/en active Active
- 2014-08-26 US US14/914,472 patent/US10668218B2/en active Active
- 2014-08-26 EP EP14755665.8A patent/EP3038676A1/en active Pending
- 2014-08-26 WO PCT/EP2014/068023 patent/WO2015028441A1/en active Application Filing
- 2014-08-26 KR KR1020167007464A patent/KR102461754B1/en active IP Right Grant
- 2014-08-26 BR BR112016003310-8A patent/BR112016003310B1/en active IP Right Grant
- 2014-08-26 JP JP2016537254A patent/JP6764786B2/en active Active
- 2014-08-26 RU RU2016111378A patent/RU2689762C2/en active
- 2014-08-26 CN CN201480047825.7A patent/CN105492046B/en active Active
- 2014-08-26 MX MX2016002588A patent/MX2016002588A/en unknown
- 2014-08-26 CA CA2921926A patent/CA2921926A1/en not_active Abandoned
- 2014-08-27 TW TW103129448A patent/TWI655012B/en active
- 2014-08-27 AR ARP140103211A patent/AR097469A1/en active IP Right Grant
-
2016
- 2016-02-02 IL IL243906A patent/IL243906B/en active IP Right Grant
- 2016-09-29 HK HK16111379.0A patent/HK1223048A1/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1561832A1 (en) * | 1967-04-01 | 1970-04-02 | Hennefer Schreibwaren Fabrik R | Push-in cap for pens |
WO1988008725A1 (en) * | 1987-05-08 | 1988-11-17 | Wilhelm Haselmeier Gmbh + Co. | Injection device with a loading element and a second setting element |
US20040015038A1 (en) * | 2000-09-01 | 2004-01-22 | Pierre-Marie Lemer | Device for protecting a syringe, in particular for a syringe used for injecting radioactive product (s) |
EP1603611B1 (en) * | 2003-03-03 | 2008-05-07 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for drug delivery device |
US20070265579A1 (en) * | 2006-05-10 | 2007-11-15 | Gennady Kleyman | Dental syringe |
WO2008128645A1 (en) * | 2007-04-18 | 2008-10-30 | Sanofi-Aventis Deutschland Gmbh | Injection device for delivering a medication |
CN201097144Y (en) * | 2007-08-17 | 2008-08-06 | 深圳市宝安区新安安泰时计制品厂 | Watch |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10668218B2 (en) | 2013-08-29 | 2020-06-02 | Sanofi-Aventis Deutschland Gmbh | Housing and cap for an injection device made of an outer metal part and an inner plastic part |
WO2017207504A1 (en) * | 2016-05-31 | 2017-12-07 | Sanofi-Aventis Deutschland Gmbh | Cap assembly for a drug delivery device and method for assembling a cap assembly |
KR20190013941A (en) * | 2016-05-31 | 2019-02-11 | 사노피-아벤티스 도이칠란트 게엠베하 | Button for drug delivery device and method for assembling button for drug delivery device |
KR20190015365A (en) | 2016-05-31 | 2019-02-13 | 사노피-아벤티스 도이칠란트 게엠베하 | Cap assembly for drug delivery device and assembly method of cap assembly |
US11241543B2 (en) | 2016-05-31 | 2022-02-08 | Sanofi-Aventis Deutschland Gmbh | Button for a drug delivery device and method for assembling a button for a drug delivery device |
US11291776B2 (en) | 2016-05-31 | 2022-04-05 | Sanofi-Aventis Deutschland Gmbh | Cap assembly for a drug delivery device and method for assembling a cap assembly |
KR102410824B1 (en) | 2016-05-31 | 2022-06-21 | 사노피-아벤티스 도이칠란트 게엠베하 | Button for drug delivery device and method of assembling button for drug delivery device |
WO2023078855A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Electronic module, drug delivery device and method for operating an electronic module |
WO2023078860A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Drug delivery device, drug reservoir unit and set |
WO2023078852A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Drug delivery device, drug reservoir unit and set |
WO2023078845A1 (en) | 2021-11-03 | 2023-05-11 | Sanofi | Drug delivery device |
Also Published As
Publication number | Publication date |
---|---|
EP3038676A1 (en) | 2016-07-06 |
IL243906B (en) | 2021-04-29 |
US10668218B2 (en) | 2020-06-02 |
IL243906A0 (en) | 2016-04-21 |
CN105492046B (en) | 2019-07-05 |
RU2689762C2 (en) | 2019-05-28 |
RU2016111378A3 (en) | 2018-05-29 |
CN105492046A (en) | 2016-04-13 |
AU2014314290B2 (en) | 2018-11-08 |
BR112016003310B1 (en) | 2022-08-16 |
TW201529116A (en) | 2015-08-01 |
US20160206820A1 (en) | 2016-07-21 |
BR112016003310A2 (en) | 2017-08-01 |
MX2016002588A (en) | 2016-06-14 |
RU2016111378A (en) | 2017-10-02 |
JP2016529013A (en) | 2016-09-23 |
AR097469A1 (en) | 2016-03-16 |
HK1223048A1 (en) | 2017-07-21 |
AU2014314290A1 (en) | 2016-03-10 |
KR102461754B1 (en) | 2022-11-02 |
JP6764786B2 (en) | 2020-10-07 |
CA2921926A1 (en) | 2015-03-05 |
KR20160047508A (en) | 2016-05-02 |
TWI655012B (en) | 2019-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10265479B2 (en) | Drug delivery device | |
US11052200B2 (en) | Cap for a drug delivery device | |
AU2014314290B2 (en) | Housing and cap for an injection device made of an outer metal part and an inner plastic part | |
US10617829B2 (en) | Cap assembly for a drug delivery device and drug delivery device | |
US10653840B2 (en) | Housing and drug delivery device herewith | |
US11291776B2 (en) | Cap assembly for a drug delivery device and method for assembling a cap assembly | |
US11241543B2 (en) | Button for a drug delivery device and method for assembling a button for a drug delivery device | |
AU2018229746B2 (en) | Cap assembly for a drug delivery device, kit for assembling a cap, method for assembling a cap and drug delivery device comprising a cap assembly. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201480047825.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14755665 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 243906 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2921926 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016537254 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14914472 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2016/002588 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014755665 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014755665 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016003310 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014314290 Country of ref document: AU Date of ref document: 20140826 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20167007464 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2016111378 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112016003310 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160217 |